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Abstract
Background: Inherited bleeding disorders (IBD) consist of a group of rare heterogeneous diseases, which require
treatment for life. Management of these disorders is complex and costly. Therefore, good quality data of the
affected population is crucial to guide policy planning. The aim of this manuscript is to describe the impact of a
national, web-based registry – the Hemovidaweb Coagulopatias (HWC) – in the management of the IBD in Brazil.
Methods: The system was developed in PHP 5.0 language and is available on the internet at http://coagulopatiasweb.
datasus.gov.br. The system was validated in September 2008 and launched nationally with input from January 1, 2009.
HWC collects variables related to socio-demographic, clinical, laboratory and treatment data of patients with IBD.
Results: Within 7 years, there was an increment of 90.8% on the diagnosis of IBD altogether, which increased from
11,040 in December 2007 to 21,066 in December 2014. This is now the fourth and third largest world population of
patients with haemophilia and von Willebrand’s disease (vWD), respectively, according to the most recent (2015)
Annual Global Survey of the World Federation of Hemophilia. The data collected provided the basis for planning and
implementing home therapy, prophylaxis and immune tolerance induction (ITI), recently initiated in Brazil.
Conclusion: HWC was an effective tool in the increment of registration of patients with IBD in Brazil. Furthermore,
it was essential to support policy planning, monitoring, evaluation and treatment. Future development should focus
on surveillance, health outcomes and research. Every country should implement a national registry on IBD.
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Background
Inherited bleeding disorders (IBD) are heterogeneous
group of rare diseases characterized by bleeding mani-
festations of variable severity. IBD require treatment for
life, which is complex and costly. In most of the cases,
treatment requires intravenous infusion of factor con-
centrates (FC) and/or blood products at prophylactic
and/or episodic basis.
Clinical registries have a wide application in the man-
agement of IBD. Increasingly, national registries are pro-
viding patients, clinicians and governments an insight
into the needs of patients, an important tool to guide
health policies. Keeping updated registries is important
for planning care, monitoring the effective use of re-
sources, health outcomes and implementing surveillance
[1]. Registries are particularly important for Government
planning when a substantial amount of public resource
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is spent on groups of rare diseases, such as it is the case
of the IBD.
Within the last years, there has been a substantial pro-
gress on the implementation of registries devoted to IBD
in many countries [2–10]. However, many countries still
do not have a national registry devoted to IBD [11] nor
provide registry with good quality data [12]. In Brazil,
until December 2008, the registration of patients with
IBD was performed manually using spreadsheets, which
had several limitations, such as difficulty in updating
information, typing errors, duplications, and others. By
noticing the need to improve data collection, the Minis-
try of Health (MoH), set up a modern, easily accessible
web-based national registry of patients with IBD, the
HEMOVIDAWeb Coagulopatias (HWC).
This report aims at describing the development and
impact of HWC on registration, diagnosis and manage-
ment of IBD in Brazil. To our concern this is the first
report which shows an impact of a national web-based




This is a descriptive study aimed at reporting the im-
pact of a web-based registry of IBD in comparison
with previous data manually-collected in Excel spread
sheets [6]. Patients’ data were entered by health
professionals working in the haemophilia treatment
centers (HTCs).
The program of IBD in Brazil
The MoH manages the Program of IBD in Brazil. The
main roles of the Program are: (i) purchase of FC and
distribution to HTCs, (ii) promotion of education of
multiprofessional teams dealing with IBD, (iii)
organization of guidances on management of IBD and
(iv) provision of an updated registry.
The management and treatment of patients with IBD
are guaranteed by the Brazilian Public National Health
System – named Sistema Único de Saúde (SUS). Most
patients with IBD are attended in HTCs located in the
26 Brazilian States and 1 Federal District. Patients who
have private health insurance and milder forms of IBD
are likely to be attended at private clinics. However, due
to the fact that approximately 100% of FC purchased in
Brazil is acquired centrally by the MoH, patients who
demand treatment are attended at the HTCs. Therefore,
it is reasonable to assume that approximately 100% of
patients with moderate/severe forms of IBD are treated
in the public sector (HTCs). For this, it is required that
all patients are registered with a HTC in order to receive
treatment.
The HEMOVIDAWeb Coagulopatias system
The development of HWC started in early 2008 and was
implemented from January 2009. Its development and
management is funded by the MoH. It was triggered by
the need of developing a national registry capable of col-
lecting reliable clinical data of patients with IBD in the
country and monitoring FC use.
The system was developed in PHP 5.0 language and is
available on the internet at http://coagulopatiasweb.data
sus.gov.br. The access to the system can be reached by
using Internet Explorer 7, Mozilla Firefox or Google
Chrome. The system was validated in September 2008
followed by a national training course for users in
November 2008. It was then launched nationally with in-
put from January 1, 2009.
The system was conceived by the creation of adminis-
trative modules assessed by individual username and
password. Users signed a consent form which stated
their responsibility to confidentiality and appropriate use
of the system and data. The system contains six struc-
tured access profiles, classified as (i) Federal (MoH)
Manager, (ii) State Manager, (iii) Care Provider, (iv)
Service Provider, (v) Assistance Provider and (vi) Distri-
bution Controller. Professionals in charge of these
accesses are mainly haemophilia nurses, haemophilia
doctors and pharmacists. The States are the responsible
bodies for the provision of access profiles from ii to iv,
in a decentralized flow under their decision.
Modules
The modules were composed by two major groups:
administrative and clinical. The administrative module
was composed by: (i) registration, designed for registra-
tion of a new cases of IBD or transfer of a registered
patient to another state; (ii) data extraction; (iii) emis-
sion of reports and (iv) stock control, use and distri-
bution of FC.
The clinical module included: (i) socio-demographic
data, (ii) diagnosis, (iii) clinical complications, (iv)
laboratory tests and (v) treatment.
Variables collected in the clinical module
Socio-demographic variables included: name, date of
birth, sex, age, race, education, marital status, occupa-
tion, weight, height and body mass index.
The list of diagnosis comprised: HA or HB (if severe,
moderate, mild or unknown), classification according to
[13]; von Willebrand’s disease (vWD) (if types 1, 2A, 2B,
2 N, 2 M, 3, platelet type or unknown); afibrinogenae-
mia, hypofibrinogenaemia, dysfibrinogenemia, deficien-
cies of factors II, V, VII, X, XI, XII, XIII, high molecular
weight kininogen, prekallikrein, PAI-1, combined defi-
ciencies, deficiency of vitamin K-dependent factors,
acquired inhibitors, Bernard-Soulier syndrome, Glanzmann’s
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thrombasthenia, other platelet disorders and other un-
diagnosed bleeding conditions. Variables on complica-
tions include: muscle skeletal complications; use of
catheter; inhibitor status (screening and titration) and
death (with causes).
Laboratory tests include: ABO blood group and Rh
status; vaccination status for hepatitis A and B; sero-
logical tests for human immunodeficiency virus (HIV),
human T lymphotropic virus (HTLV), hepatitis B and C.
Whether any of these diseases are confirmed, we collect
information regarding treatment.
Finally, in the treatment module, we collect: use of FC
by type, data of infusion and quantity (in international
units [IU] or other unit), lot, motive of use (surgery,
trauma, bleeding, type of bleeding) and category of use
(if home treatment, prophylaxis, episodic, hospital use,
immune tolerance induction [ITI]). This module in-
cludes a tool for stock control, use and distribution of
FC which is linked to MoH stock system.
Results
The impact of the system on the registration of patients
and on the prevalence of IBD
In the first months after the implementation of the sys-
tem, the number of registered patients with all forms of
IBD increased 30.8% rising from 11,040 patients in
December 2007 when the registrations were still
performed in Excel spreadsheets to 14,436 patients in
December 2009, the first year of use of HWC (Fig. 1).
After 7 years, there was an increment of 90.8% in the
registration of patients with all forms of IBD (from
11,040 in December 2007 to 21,066 in December 2014)
(Fig. 1).
Following a sharp increase on the registration of cases
from 2007 to 2010, we observe a tendency to a plateau
from 2011, with a mean of 7% (variation, 6.5–8.0%) of
new cases of IBD registered yearly from 2011–2014
(Fig. 1). This information is crucial for policy planning,
acquisition of FC and estimation of the number of
patients who will need prophylaxis and might develop
inhibitors, according to reported incidences.
As expected, the prevalence coefficient of HA e HB
also changed as a reflection of the increment in registra-
tion. The prevalence coefficient of HA increased from
0.73/10,000 in 2007 [6] to 1.00/10,000 males in 2014
[14]. For HB, the coefficient was 0.48/35,000 in 2007 [6]
and 0.70/35,000 males in 2014 [14]. Differences between
states remain, although less pronounced in 2014 when
compared with 2007 (data not shown).
Historical data (2002–2014) on the relative distribu-
tion of the IBD showed a reduction in the percentage of
HA and HB (in relation to all IBD) from 70.94 to 45.65%
and 11.62 to 8.93%, respectively and an increase in the
percentage of vWD and other IBD from 11.36 to 31.06%
and 2.65 to 14.36%, respectively (Table 1). Rare bleeding
disorders and platelet disorders account for the majority
of the reported “other IBD” and their prevalence is de-
tailed in Table 2.
The impact of the system on clinical data of IBD
In December 2014, most (62.6%) patients registered with
IBD are female (after excluding all PWH) and 39% are in
the age range of 20–39 years. In December 2014, severe,
moderate and mild HA accounted for 38.3, 23.7 and
25.0% of patients, respectively. Severity was not in-
formed in 13.0% of the patients, slightly lower than re-
ported in 2007, 17.5% [6]. Severe, moderate and mild
HB accounted for 31.4, 33.4 and 22.2%, respectively.
Similar to HA, severity was not informed in 12.9% of the
patients, slightly lower than reported in 2007, 14.2% [6].
In 2014, 77.8 and 79.0% of patients with HA and HB,
respectively, were tested for inhibitors (screening test),
when compared with 2007, which were 58.6 and
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Fonte: Ministério da Saúde, 
Coordenação Geral de 
Sangue e Hemoderivados e 
Hemovida Web – Coagulopatias.
Fig. 1 Prevalence of inherited bleeding disorders in Brazil, 2002–2014. The black line represents the increment percentage in the registration
of patients from the previous year to the following year shown disclosed. There was a plateau from 2011 in the percentage of registration of
new cases
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1.4% (n = 27) of patients with HA and HB, respect-
ively, had a positive inhibitor screening test. Inhibitor
titration was recorded in 77.4% (n = 540) of patients
with HA, who had a positive screening test (n = 698).
Inhibitors were of low-response (less than 5 BU/mL)
in 43.7% (n = 236) and of high-response (>5 BU /mL)
in 54.4% (n = 294) of patients with HA; in 10 patients
(1.9%) titration was negative. Inhibitor titration was
recorded in 70.3% (n = 19) of patients with HB who
had a positive screening test (n = 27). Of these, 52.6%
(n = 10) and 42.1% (n = 8) were low and high
responders, respectively.
The impact of the system on the assessment of factor
concentrate use
The use of FC and other procoagulants (such as desmo-
pressin acetate and tranexamic acid) are routinely
recorded for all registered patients with IBD who receive
treatment.
Regarding the categories of use of FVIII concentrate in
2014, secondary prophylaxis, home treatment, infusion
in the HTC, ITI, hospital treatment and primary prophy-
laxis accounted for 49.9, 27.1,10.6, 8.0, 3.0 and 1.4%, re-
spectively. For FIX concentrate, secondary prophylaxis,
home treatment, infusion in the HTC, hospital treat-
ment and primary prophylaxis accounted for 43.2, 29.0,
20.0, 6.8 and 1.0% of use in 2014, respectively.
When all PWHA (n = 9,616) and all PWHB (n = 1,881)
were considered, mean use of FVIII and FIX concen-
trates per patient was 60,901 IU and 51,562 IU, respect-
ively in 2014. However, 6,492/9,616 (67.5%) PWHA used
FVIII concentrate in 2014, accounting for a (real) mean
use of 90,207 IU of FVIII concentrate per patient. For
PWHB, 1,250/1,875 (66.7%) used FIX concentrate in
2014, accounting for a (real) mean use of 77,343 IU per
patient.
Furthermore, in 2014, 5.9, 24.1 and 65.2% of FVIII
concentrate was used for the treatment of mild, moder-
ate and severe PWHA, respectively. Patients with no in-
formation on the severity of HA used 4.8% of the
totality of FVIII concentrate consumed in 2014. Regard-
ing FIX concentrate, 8.1, 37.8 and 49.1% were used for
the treatment of mild, moderate and severe PWHB, re-
spectively. Patients with no information on the severity
of HB used 5.0% of the totality of FIX concentrate con-
sumed in 2014.
The increment of the purchase of FVIII and IX con-
centrates after 2010 in Brazil reflects the data on the per
capita use of these products. In 2014, per capita use of
FVIII and FIX in Brazil was 2.89 and 0.48, respectively
[14]. This represents an increment of 136.9 and 84.6%
when compared with data from 2010, which were 1.22
and 0.26, respectively [14]. Currently, 69.8 and 30.2% of
PWHA are treated with recombinant and plasma-
derived FVIII concentrate, respectively. The totality of
PWHB are treated with plasma-derived FIX concentrate.
Table 1 Historical prevalence of inherited bleeding disorders, Brazil, 2002-2014
Year Haemophilia A Haemophilia B von Willebrand’s disease Other inherited bleeding disordersa Not informed Total
N % N N N % N % N % N %
2002 5,411 70.95 886 11.62 866 11.36 202 2.65 261 3.42 7,626 100
2007 6,881 62.33 1,291 11.69 2,333 21.13 316 2.86 219 1.98 11,040 100
2009 7,905 54.76 1,516 10.50 3,822 26.48 1,015 7.03 178 1.23 14,436 100
2010 8,369 52.06 1,609 10.01 4,451 27.69 1,437 8.94 210 1.31 16,076 100
2011 8,848 50.94 1,723 9.92 4,934 28.41 1,865 10.74 0 0.00 17,370 100
2012 9,122 49.17 1,801 9.71 5,445 29.35 2,184 11.77 0 0.00 18,552 100
2013 9,348 47.33 1,838 9.31 5,976 30.26 2,589 13.11 0 0.00 19,751 100
2014 9,616 45.65 1,881 8.93 6,544 31.06 3,025 14.36 0 0.00 21,066 100
aThis includes rare bleeding disorders, platelet disorders, hemophilia carriers and unknown bleeding disorders
Table 2 Prevalence of rare bleeding and platelet disorders




Factor II deficiency 13 0.6
Factor V deficiency 157 7.7
Combined factor V and VIII deficiency 27 1.1
Factor VII deficiency 723 35.4
Factor X deficiency 88 4.3
Factor XI deficiency 165 8.1
Factor XIII deficiency 61 3.1
Deficiency of vitamin K-dependent factors 13 0.6
Other combined deficiencies 46 2.3
Bernard Soulier syndrome 59 2.9
Glanzmann’s trombastenia 244 12.1
Other platelet disorders 359 17.6
Total 2,041 100
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The impact of the system on the implementation of
prophylaxis and immune tolerance
Prophylaxis for severe and moderately-severe PWHA and
PWHB (<2% of factor activity level) and ITI for PWHA
and persistent inhibitors were implemented in Brazil in
the end of 2011. Both programs were made available due
to the provision of data on new cases of HA and HB,
haemophilia severity and inhibitor development from
January 2009. Since the registration of new cases is per-
formed via web, in real time, upon inclusion of the PWH
in the system and information on severity, it is possible to
identify PWH who will require long-term prophylaxis.
Furthermore, by identifying new patients with inhibitors it
is possible to include them on ITI at an early stage. By De-
cember 2015, we had 383 PWHA and PWHB on primary
prophylaxis and 240 patients with hemophilia A on ITI.
Concerning ITI, the first phase of the program in-
cluded patients with long-standing history of inhibitors,
selected from the database according to the inclusion
criteria. More recently, as there is more awareness about
ITI program and inhibitor surveillance increased,
patients who develop inhibitor have been included earl-
ier in the course of this complication. Furthermore, the
system allows for searching candidate patients, therefore
promoting a more efficient action on the identification
of patients with inhibitors who fill the criteria for ITI.
Discussion
The implementation of HWC, a web-based national
registry had a major impact on the increment of the
registration of patients with IBD, reflected by a rise of
nearly 100% in the number of registered patients with all
forms of IBD after 7 years of its onset. Furthermore, the
system proved to be a good platform for the support of
policy planning, promotion of health care, surveillance,
allocation of resources and distribution of products.
According to the last published Annual Global Survey
2015 of the World Federation of Haemophilia (WFH),
the total number of people with identified IBD in the
world is 304,362 [15]. Within the 111 countries
surveyed, Brazil has the fourth largest population of
PWH (n = 11,857), after United States (n = 18,596), India
(n = 16,635) and China (13,624) and the third population
of patients with vWD (n = 7,223) after United States
(n = 13,845) and United Kingdom (n = 10,586) [15].
This position was been achieved after the implemen-
tation of HWC, which promoted a sharp rise in the
registration of patients with IBD.
There was a sharp increment on the prevalence of IBD
in Brazil from 2002–2014 until 2010. After 2011, there
was a plateau in the registration of “new” patients with
IBD reaching about 7.0% a year. Therefore, in the first
3 years after its implementation, HWC was an efficient
tool in the promotion of the registration of patients with
IBD who were not already registered by the HTCs. How-
ever, since a major improvement in the diagnosis of
these disorders occurred in Brazil in the same period, we
cannot rule out the role of concurrent diagnostic strat-
egies in the increment of the numbers registered.
The results here presented reflect patients’ data col-
lected from the totality of the HTCs in Brazil, which
represent of most of the patients with IBD in the coun-
try. Although we do not have the precise numbers, a
small proportion of patients with mild IBD are attended
in private clinics and therefore might not be registered
with the HTCs. However, once these patients require
treatment, they are referred to the public HTCs and are
then registered in the HWC.
HWC had an important impact on the management of
patients with IBD, reflected by the collection of reliable
data as well as acting as a platform to policy planning.
By assessing the prevalence of IBD and the mean use of
products per disease and severity it was possible to esti-
mate required budget and amount of FC needed to treat
patients. Information regarding the real-time registration
of new patients with hemophilia, its severity and new pa-
tients with inhibitors also supported implementation of
prophylaxis and ITI. Both initiatives were implemented
according to data generated by HWC. Furthermore, the
distribution of FC for the entire country as well as its
use is now easily monitored by the stock control tool,
which allows the control of distribution and use of FC
from the central stock at the MoH to the patient.
There was a prompt adherence of HWC by health
professionals in the HTCs. This was likely due to its
simplicity of use, easily accessible web-based registry,
“real-time” provision of data and feasibility to download,
save and print reports of the patients, which facilitated
the incorporation of relevant medical information into
patients’ files. Furthermore, we used a successful strategy
for qualification and training of health professionals who
worked with the system in the HTCs, which involved
annual national meetings for discussion, presentation of
data and innovations to the system. However, it is im-
portant to consider that part of the reason for a prompt
adherence might be due to the compulsory need for
registration of any patient with IBD who required use of
any pro-coagulant product from January 2009.
HWC incorporated all the mandatory parameters rec-
ommended for the implementation of a national registry,
such as personal and demographic, diagnosis and treat-
ment details, bleeding history and serology [11, 16].
Furthermore, most of the optional parameters were also
included such as joint status, death and cause of death,
vaccination status and genetic information [11].
HWC has aspects which need improvement, either
related to the (i) inclusion of additional parameters or to
(ii) qualification of data. Additional parameters should
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focus on data related to hospitalization, surgery, quality
of life assessment and genetic information. Qualification
of data is still an important issue in many registries [12].
In HWC, we noticed that some variables such as vaccin-
ation status, serology, clinical data (severity of disease,
inhibitor status, follow-up visits) and treatment data
(infusion charts, detail of prophylactic scheme and
adherence) are targets to improvement. Information on
death and mortality cause is hardly obtained by HTCs.
Furthermore, the registry does not pursue an appropri-
ate strategy for surveillance parameters known to be
important in IBD, such as inhibitor, infectious diseases,
infusion reactions nor a facility which allow patients
themselves to insert infusion data in the system.
Conclusions
HWC, a national, web-based, real-time registry on IBD,
had a major impact in the registration of IBD in Brazil
in comparison with a manually-based national registry.
Furthermore, its implementation promoted a prompt
improvement on policy planning, which enhanced the
quality of care of IBD in Brazil. We recommend all
countries to implement national registries on IBD.
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